Article
Timing issues are important when treating invasive TCC
Articles in this month's Urology Times deal with an issue of "timing"when determining the treatment of invasive transitional cell carcinoma ofthe bladder.
Related Videos
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
BRCA Mutations in mHSPC: Impact on Therapy Selection
Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
Defining and Managing BCG-Unresponsive NMIBC
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Yahir A. Santiago-Lastra, MD, discusses barriers to vaginal estrogen access
Related Content
